The primary hyperparathyroidism and its complications: Substantiation of funding volume for hospital pharmacotherapy

This study investigates factors influencing the cost of pharmacotherapy for primary hyperparathyroidism (PHPT) in a hospital setting to optimize therapeutic strategies and rationalize financing. The study was conducted from 2020 to 2023 and included 200 patients with PHPT from two hospitals in Moscow, Russia. The key aspects for analysis were demographic profiles, treatment methods, complications, and associated costs. The majority of patients (52.1%) were aged 60-74 years, while only 2.0% were aged 75 or older. The most frequently prescribed medications were cardiovascular drugs (33.5%) and vitamin supplements (25.1%). Colecalciferol (13.5%), bisoprolol (6.8%), and cinacalcet (4.9%) were the most common individual medications. The study revealed that the cost of conservative treatment without complications was twice that of surgical treatment. These models can aid in justifying and optimizing PHPT treatment financing in hospital settings. The findings highlight the importance of individualized treatment approaches and cost optimization strategies.